The evaluation of the efficacy of Alflutop in the complex treatment of patients with chronic lower back pain (the observational study ZEITNOT)

Samartsev, I. N.; Zhivolupov, S. A.; Баранцевич, Е. Р.; Danilov, А B

doi:10.17116/jnevro202112102124

Cited by 9 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of SSFE in the complex pharmacotherapy of back pain has been shown, which is associated with its ability to attenuate afferent nociceptive activity by reducing inflammation in the spinal structures and decreasing central sensitization [ 88 , 89 ]. The positive effect of the drug is its long-term (up to 1 month after the end of treatment) analgesic effect.…”

Section: Purified Bioactive Extracts Of Small Sea Fish: a Promising T...mentioning

confidence: 99%

Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis

Golovach,

Rekalov,

Akimov

et al. 2023

Reumatologia

View full text Add to dashboard Cite

Post-traumatic osteoarthritis (PTOA), a disorder of the synovium, subchondral bone, and cartilage that affects the entire joint, constitutes approximately 12% of all cases of symptomatic osteoarthritis. This review summarizes the pathogenetic mechanisms that underlie the positive influence of chondroitin sulphates (CSs) on PTOA as means of preventive and therapeutic treatment. Mechanisms of PTOA development involve chondrocytes undergoing various forms of cell death (apoptosis, pyroptosis, necroptosis, ferroptosis and/or necrosis). Chondroitin sulphates are a class of glycosaminoglycans that improve the structure and function of cartilage and subchondral bone, which is associated with their ability to decrease the activation of NF-κB and p38 MAPK, and up-regulate Nrf2. Standardized small fish extract (SSFE) is an example of the drugs that can attenuate NF-κB-mediated systemic inflammation, potentially helping to reduce joint inflammation and cartilage degradation, improve joint function, and alleviate pain and disability in patients with these conditions.

show abstract

Section: Purified Bioactive Extracts Of Small Sea Fish: a Promising T...mentioning

confidence: 99%

Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis

Golovach,

Rekalov,

Akimov

et al. 2023

Reumatologia

View full text Add to dashboard Cite

show abstract

Chronic back pain as a spinal osteoarthritis manifestation: rationale and practice of symptomatic slow acting drugs for osteoarthritis use

Karateev¹

2022

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Chronic non-specific back pain (CNBP) is the most common pathology of the musculoskeletal system, affecting from 10 to 60% of the adult population in the world, causing severe suffering, disability and a significant deterioration in the quality of life. Osteoarthritis (OA) should be considered as one of the main reasons of the development of CNBP – inflammatory and degenerative changes in the facet and sacroiliac joints, as well as the spinal column itself (in particular, osteitis of the Modic 1 type). Spinal OA is accompanied by biomechanical disturbances, nociplastic (peripheral and central sensitization) and psycho-emotional changes that form a complete picture and various CNBP phenotypes.Recognizing the leading role of OA as the cause of CNBP, it is advisable to use the same therapeutic approaches in this syndrome as in OA of peripheral joints. In particular, it is necessary to consider the use of symptomatic slow acting drugs for osteoarthritis (SYSADOA) in CNBP as the main pathogenetic therapy.Alflutop is one of the most popular parenteral SYSADOA widely used in Russian practice. This drug has a good evidence base: this review presents data from 12 clinical trials of Alflutop in CNBP (n=1479), which confirmed its efficacy and safety.

show abstract

Management of patients with subacute back pain: how to effectively prevent chronicity

Головачева

Golovacheva

Parfenov

2022

RJTAO

View full text Add to dashboard Cite

The evaluation of the efficacy of Alflutop in the complex treatment of patients with chronic lower back pain (the observational study ZEITNOT)

Cited by 9 publications

References 22 publications

Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis

Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis

Chronic back pain as a spinal osteoarthritis manifestation: rationale and practice of symptomatic slow acting drugs for osteoarthritis use

Management of patients with subacute back pain: how to effectively prevent chronicity

Contact Info

Product

Resources

About